US Congress Senate Bill 474 (Prior Session Legislation)

---

Spectrum: Partisan Bill (Democrat 13-0)
Status: Introduced on February 13 2019 - 25% progression, died in committee
Action: 2019-02-13 - Read twice and referred to the Committee on Finance.
Pending: Senate Finance Committee
Text: Latest bill text (Introduced) [PDF]

Requires manufacturers of drugs with specified percentage increases in their wholesale costs to submit to the Centers for Medicare & Medicaid Services (CMS) written justification for certain increases in drug prices. The CMS shall publish each submission, together with an easily understandable summary, on its website. Certain proprietary information may be excluded from publication, as specified by the bill. A manufacturer that does not comply with the bill's requirements shall be subject to civil monetary penalties.

Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act of 2019

Sen. Ron Wyden [D-OR]	Sen. Benjamin Cardin [D-MD]	Sen. Thomas Carper [D-DE]	Sen. Christopher Coons [D-DE]
Sen. Tammy Duckworth [D-IL]	Sen. Amy Klobuchar [D-MN]	Sen. Robert Menendez [D-NJ]	Sen. Debbie Stabenow [D-MI]
Sen. Jon Tester [D-MT]	Sen. Kirsten Gillibrand [D-NY]	Sen. Catherine Cortez Masto [D-NV]	Sen. Tina Smith [D-MN]
Sen. Gary Peters [D-MI]

Date	Chamber	Action
2019-02-13	Senate	Read twice and referred to the Committee on Finance.

Type	Source
Summary	https://www.congress.gov/bill/116th-congress/senate-bill/474/all-info
Text	https://www.congress.gov/116/bills/s474/BILLS-116s474is.pdf